1-((chloromethyl)sulfonyl)-4-methylpiperazine | 3967-02-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 1-((chloromethyl)sulfonyl)-4-methylpiperazine
• 英文别名: 1-chloromethanesulfonyl-4-methyl-piperazine；1-Chloromethanesulfonyl-4-methylpiperazine；1-(chloromethylsulfonyl)-4-methylpiperazine
• CAS: 3967-02-0
• 化学式: C₆H₁₃ClN₂O₂S
• 分子量: 212.7
• InChiKey: YCWREUFSOKGQCH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  49
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-((chloromethyl)sulfonyl)-4-methylpiperazine 、 3-甲基苯甲醛 在 potassium hydride 作用下， 生成 1-Methyl-4-((2R,3R)-3-m-tolyl-oxiranesulfonyl)-piperazine
  参考文献：
  名称：

  New antifilarial agents. 1. Epoxy sulfonamides and ethynesulfonamides

  摘要：

  Two series of 2-substituted 1,2-epoxyethanesulfonamides 2 and ethynesulfonamides 5 were synthesized and evaluated for their antifilarial activity. The trans epoxides 2T were stereospecifically prepared by a Darzens reaction between aldehydes and halomethanesulfonamides. The cis isomers 2c were obtained from ethynesulfonamides 5 by semihydrogenation followed by KOCl epoxidation. 2-Substituted ethynesulfonamides 5 were synthesized from appropriate trans-ethenesulfonamides by a bromination/dehydrobromination sequence. These products, as well as several synthetic intermediates, were evaluated for antifilarial activity against Molinema dessetae either in vivo in its natural host, the rodent Proechimys oris, or in vitro by a new test using cultures of the infective larvae. Most of the epoxides 2T and acetylenic derivatives 5 bearing a 2-aryl substituent were active in vitro. Among these compounds, four epoxides 2T and one acetylenic derivative 5 showed marked macrofilaricidal activity in vivo without any microfilaricidal activity. The differences between the in vivo and in vitro results may be due, in part, to the low chemical stability of the epoxy sulfonamides 2T. Despite this limitation, the activities observed in this reliable animal model suggest further development and testing of both series 2T and 5 as macrofilaricides.

  DOI：

  10.1021/jm00395a010
• 作为产物：
  描述：

  N-甲基哌嗪 、 氯甲磺酰氯 在 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 16.0h， 以64%的产率得到1-((chloromethyl)sulfonyl)-4-methylpiperazine
  参考文献：
  名称：

  下一代缺氧细胞放射增敏剂：硝基咪唑烷基磺酰胺

  摘要：

  立体定向身体放疗等放疗领域的创新，以及放射免疫肿瘤学的出现，为经典的模拟氧放射增敏剂带来了新的机遇。缺氧肿瘤细胞在放射疗法抗性和免疫应答抑制中的作用继续证明肿瘤缺氧是一种真正的但尚未开发的药物靶标。临床上仅将尼莫拉唑用作放射增敏剂，并且尚无开发中的新的放射增敏剂。在这里，我们目前对新型硝基咪唑烷基磺酰胺类药物进行调查，并记录它们的细胞毒性和在体外对缺氧肿瘤细胞放射增敏的能力。我们使用磷酸盐前药方法来增加水溶性并改善肿瘤药物的递送。

  DOI：

  10.1021/acs.jmedchem.7b01678

文献信息

• [EN] DUAL NK1/NK3 ANTAGONISTS FOR TREATING SCHIZOPHRENIA<br/>[FR] ANTAGONISTES DOUBLES DES RECEPTEURS NK1/NK3 POUR TRAITER LA SCHIZOPHRENIE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2005002577A1

  公开（公告）日：2005-01-13

  The use of compounds of the general formula wherein the substituents are as described in claim 1 or pharmaceutically active acid-addition salts thereof for the preparation of medicaments for the treatment of schizophrenia.

  使用一般式化合物，其中取代基如权利要求1中所述，或其药用活性酸盐，用于制备治疗精神分裂症的药物。
• SUBSTITUTED PYRIMIDINES AND TRIAZINES AND THEIR USE IN CANCER THERAPY
  申请人：Rewcastle Gordon William

  公开号：US20110053907A1

  公开（公告）日：2011-03-03

  Provided herein are substituted pyrimidine and triazine derivatives, including bicyclic pyrimidine derivatives, their pharmaceutical compositions, their preparation, and their use as agents or drugs for cancer therapy, either alone or in combination with radiation and/or other anticancer drugs. In one embodiment, the pyrimidine and triazine derivatives are morpholino-pyrimidine, morpholino-triazine, pyridyl-pyrimidine, and pyridyl-triazine derivatives which are selective irreversible inhibitors of the p110α isoform of PI3K.

  本文提供了替代嘧啶和三嗪衍生物，包括双环嘧啶衍生物，它们的药物组合物，其制备以及它们作为单独的癌症治疗剂或药物的用途，或与放射线和/或其他抗癌药物组合使用。在一种实施例中，嘧啶和三嗪衍生物是吗啡啶基嘧啶，吗啡啶基三嗪，吡啶基嘧啶和吡啶基三嗪衍生物，它们是PI3K的p110α亚型的选择性不可逆抑制剂。
• DUAL NK1/NK3 RECEPTOR ANTAGONISTS
  申请人：Hoffmann Torsten

  公开号：US20110178055A1

  公开（公告）日：2011-07-21

  The present invention provides a method for the treatment of schizophrenia which comprises administering a compound of formula wherein the substituents are as described herein or a pharmaceutically active acid-addition salt thereof. In particular, the invention provides methods for treating both positive and negative symptoms of schizophrenia through dual inhibition of NK1 and NK3 receptors. The invention also provides novel compounds with formula I and methods for preparing compounds of the invention.

  本发明提供了一种治疗精神分裂症的方法，该方法包括给予式中所述的取代基如此描述或其药物活性酸加成盐。特别地，本发明通过双重抑制NK1和NK3受体提供了治疗精神分裂症的方法，包括治疗阳性和阴性症状。本发明还提供了式I的新化合物以及制备本发明化合物的方法。
• BRIENE, MARIE-JOSEPHE;VARECH, DANIEL;LECLERCQ, MARTINE;JACQUES, JEAN;BADE+, J. MED. CHEM., 30,(1987) N 12, 2232-2239
  作者：BRIENE, MARIE-JOSEPHE、VARECH, DANIEL、LECLERCQ, MARTINE、JACQUES, JEAN、BADE+

  DOI：——

  日期：——
• ——
  作者：JACQUES J.、 VARECH D.、 BRIENNE M. -J.、 GAYRAL PH.

  DOI：——

  日期：——